Biodexa Pharmaceuticals Plc Quick Ratio (BDRX) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Biodexa Pharmaceuticals Plc  (NASDAQ: BDRX)

Biodexa Pharmaceuticals Plc's Quick Ratio

BDRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Biodexa Pharmaceuticals Plc's Cash & cash equivalent, this led to improvement in Biodexa Pharmaceuticals Plc's Quick Ratio to 1.89, Quick Ratio remained below Biodexa Pharmaceuticals Plc average.

Within Major Pharmaceutical Preparations industry 320 other companies have achieved higher Quick Ratio than Biodexa Pharmaceuticals Plc in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 1530, from total ranking in the third quarter 2025 at 2711.

Explain Quick Ratio?
How much Cash & cash equivalents BDRX´s has?
What are BDRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BDRX Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 21.75 % 30.76 % 21.75 % 30.76 % -9.61 %
Y / Y Cash & cash equivalent Change 417.34 % 314.68 % 308.92 % 314.68 % -72.08 %
Quick Ratio MRQ 1.89 1.41 1.5 1.41 0.45
BDRX's Total Ranking # 1530 # 2711 # # #
Seq. Current Liabilities Change -25.63 % 34.47 % -25.63 % 63.72 % -20.13 %
Seq. Cash & cash equivalent Change -0.36 % 26.97 % -21.24 % 419.23 % -20.13 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 321
Healthcare Sector # 565
Overall Market # 1530


Quick Ratio Statistics
High Average Low
5.83 2.21 0.45
0   (Dec 31 2024)




Financial Statements
Biodexa Pharmaceuticals Plc's Current Liabilities $ 6 Millions Visit BDRX's Balance sheet
Biodexa Pharmaceuticals Plc's Cash & cash equivalent $ 12 Millions Visit BDRX's Balance sheet
Source of BDRX's Sales Visit BDRX's Sales by Geography


Cumulative Biodexa Pharmaceuticals Plc's Quick Ratio

BDRX's Quick Ratio for the trailling 12 Months

BDRX Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 26.76 % 19.12 % 7.1 % 0.31 % -10.49 %
Y / Y Cash & cash equivalent TTM Growth 336.2 % 118.37 % 21.82 % -25.4 % -67.12 %
Quick Ratio TTM 1.53 1.25 1.01 0.77 0.45
Total Ranking TTM # 4623 # 3670 # # #
Seq. Current Liabilities TTM Growth 3.96 % 7.54 % 4.45 % 8.55 % -2.31 %
Seq. Cash & cash equivalent TTM Growth 26.97 % 34.16 % 36.58 % 87.48 % -36.44 %

Quick ratio ranking by company, industry and sector >> Back to BDRX Financial Strength Comparisons >> Go to Compare BDRX Quick Ratio to its Competitors

On the trailing twelve months basis BDRX Cash & cash equivalent more than doubled by 417.34 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Biodexa Pharmaceuticals Plc's Quick Ratio to 1.53, Quick Ratio remained below BDRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 485 other companies have achieved higher Quick Ratio than Biodexa Pharmaceuticals Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3670 to 4623.

Explain Quick Ratio?
How much Cash & cash equivalents BDRX´s has?
What are BDRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 486
Healthcare Sector # 994
Within the Market # 4623


trailing twelve months Quick Ratio Statistics
High Average Low
5.83 2.22 0.45
(Dec 31 2021)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Silence Therapeutics Plc  5.20 $ 85.114  Millions$ 16.359  Millions
Palvella Therapeutics Inc   5.11 $ 57.982  Millions$ 11.344  Millions
Transcode Therapeutics Inc   5.10 $ 17.814  Millions$ 3.494  Millions
Enveric Biosciences Inc   5.09 $ 4.677  Millions$ 0.918  Millions
Assembly Biosciences Inc   5.09 $ 248.106  Millions$ 48.780  Millions
Atossa Therapeutics Inc   5.02 $ 41.409  Millions$ 8.255  Millions
Lyell Immunopharma Inc   5.00 $ 247.220  Millions$ 49.412  Millions
Sionna Therapeutics Inc   4.99 $ 58.451  Millions$ 11.712  Millions
Sensei Biotherapeutics Inc   4.98 $ 21.184  Millions$ 4.251  Millions
Kiora Pharmaceuticals Inc   4.93 $ 17.089  Millions$ 3.467  Millions
Zevra Therapeutics Inc   4.86 $ 191.011  Millions$ 39.277  Millions
Rafael Holdings Inc  4.85 $ 52.769  Millions$ 10.877  Millions
Catalyst Pharmaceuticals Inc   4.82 $ 709.171  Millions$ 147.152  Millions
Cytokinetics Incorporated  4.81 $ 882.221  Millions$ 183.341  Millions
Maravai Lifesciences Holdings Inc   4.72 $ 216.890  Millions$ 45.917  Millions
Oragenics Inc   4.70 $ 8.400  Millions$ 1.786  Millions
Arvinas Inc   4.65 $ 685.400  Millions$ 147.300  Millions
Lexicon Pharmaceuticals Inc   4.61 $ 96.230  Millions$ 20.867  Millions
Amarin Corp Plcuk  4.59 $ 302.790  Millions$ 65.907  Millions
Nektar Therapeutics  4.59 $ 245.752  Millions$ 53.536  Millions
Dermata Therapeutics Inc   4.59 $ 7.522  Millions$ 1.640  Millions
Spero Therapeutics Inc   4.54 $ 40.265  Millions$ 8.868  Millions
Septerna Inc   4.50 $ 391.089  Millions$ 86.931  Millions
Briacell Therapeutics Corp   4.49 $ 17.866  Millions$ 3.978  Millions
Gyre Therapeutics Inc   4.47 $ 184.631  Millions$ 41.342  Millions
Hoth Therapeutics Inc   4.32 $ 6.247  Millions$ 1.447  Millions
Sinovac Biotech Ltd  4.31 $ 6,639.502  Millions$ 1,540.365  Millions
Kalvista Pharmaceuticals Inc   4.26 $ 220.617  Millions$ 51.757  Millions
Q32 Bio Inc   4.26 $ 48.297  Millions$ 11.346  Millions
Arcus Biosciences Inc   4.25 $ 981.000  Millions$ 231.000  Millions

Date modified: 2026-07-07T09:28:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.